Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:49:43.160Z.
Calculation as of: 2026-10-06T19:49:43.160Z.
Quote observation: 2026-10-06T19:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8daa83f2db5fafa0746e2d75675d68491b64c400a2027f88c30977eae97731f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$344.82M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$348.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$354.03M
EV/EBITDA Ratio
N/A
TTM Avg
37.95x
3Y Avg
29.61x
5Y Avg
22.14x
Market Cap
$354.03M
EV/EBITDA Ratio
6.48x
TTM Avg
7.04x
3Y Avg
7.63x
5Y Avg
8.90x
Market Cap
$359.07M
EV/EBITDA Ratio
N/A
TTM Avg
40.38x
3Y Avg
40.38x
5Y Avg
40.38x
Market Cap
$359.83M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.88M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.82M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $348.81M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $350.03M | 5.37x | 4.73x | 7.57x | 7.31x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $354.03M | N/A | 37.95x | 29.61x | 22.14x |
| Viemed Healthcare, Inc. (VMD)vs › | $354.03M | 6.48x | 7.04x | 7.63x | 8.90x |
| Ocugen, Inc. (OCGN)vs › | $353.49M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.07M | N/A | 40.38x | 40.38x | 40.38x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $359.83M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.26M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
